Stereotactic Body Radiation Therapy for Lung and Liver Oligometastases from Breast Cancer: Toxicity Data of a Prospective Non-Randomized Phase II Trial.

Davide FranceschiniTiziana ComitoAnna Di GalloVeronica VernierAntonio Marco MarzoLuciana Di CristinaBeatrice MariniLorenzo Lo FaroSara StefaniniRuggero SpotoLuca DominiciCiro FranzeseMarta Scorsetti

Published in: Current oncology (Toronto, Ont.) (2022)

The co-primary endpoint of this phase II trial was met, showing excellent tolerability of SBRT for lung and liver oligometastatic in breast cancer patients. Until efficacy data will mature with longer follow-up, SBRT should be regarded as an opportunity for oligometastatic breast cancer patients.

Keyphrases

open label
placebo controlled
radiation therapy
double blind
electronic health record
phase iii
phase ii
big data
clinical trial
oxidative stress
deep learning
breast cancer risk